Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma

ConclusionSEF is an aggressive sarcoma subtype with a poor outcome and with limited responsiveness to conventional chemotherapy. Patients with this subtype should be considered for participation in clinical trials with novel agents. Further investigation into the biology of this rare disease is required to improve outcomes.
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research